NOTRELOAD AI
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD (BETA)
  • XY Feed
  • 24-HOUR Pass →
Sign in Subscribe

FDA Approves ORZEYFUL: First Medicine to Treat the Root Cause of Narcolepsy Type 1

Twice-daily pill improves wakefulness and reduces symptoms.

FDA Approves ORZEYFUL: First Medicine to Treat the Root Cause of Narcolepsy Type 1
Credit: Kiyoshi Ota/Bloomberg
Already have an account? Sign in.
Featured/ 08/06/2026 · 7:55 AM
TAK
/ Don’t stop at just one post.

Related↓

Alkermes logo
09/08/2025 · 7:17 AM

A New Dawn for Narcolepsy: Understanding Alixorexton's Promise

Alixorexton, a new drug for narcolepsy type 1, shows great promise. It helps patients stay awake longer (28 mins, considered normal), reduces sleepiness, cataplexy, fatigue, and improves focus. It's well-tolerated and moving to Phase 3, signaling a potential new era for treatment.

/ Subscriber only
/ Read more

Feed↓

D-Wave Misses Revenue Target Despite 1,120% Bookings Surge
08/06/2026 · 8:47 AM

D-Wave Misses Revenue Target Despite 1,120% Bookings Surge

IonQ stock rose on strong results while D-Wave shares dropped after missing revenue forecasts, despite a 1,120% bookings surge in H1 2026.

/ Subscriber only
Peloton Posts First-Ever Annual Profit, but Shares Drop on Weak 2027 Outlook
08/06/2026 · 8:32 AM

Peloton Posts First-Ever Annual Profit, but Shares Drop on Weak 2027 Outlook

Peloton reports its first-ever annual net profit but shares fall as FY2027 revenue is set to decline amid ongoing subscriber losses.

/ Subscriber only
Datadog Stock Plunges Despite Strong Q2 Beat — Soft Guidance Blamed
08/06/2026 · 8:15 AM

Datadog Stock Plunges Despite Strong Q2 Beat — Soft Guidance Blamed

Despite beating estimates and lifting full-year outlook, Datadog shares fell sharply on soft Q3 sequential growth guidance.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2025
Email address Subscribe